ArticleJournal of ophthalmology2012
Antivascular endothelial growth factor agents for neovascular age-related macular degeneration.
Article in Journal of ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD.Wiener klinische Wochenschrift · 2014Trial
- Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities.Current therapeutic research, clinical and experimental · 2026Review
- SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy.Translational vision science & technology · 2022Article
- Elevated YKL-40 serum levels may contribute to wet age-related macular degeneration via the ERK1/2 pathway.FEBS open bio · 2021Article
- Combined Transplantation With Human Mesenchymal Stem Cells Improves Retinal Rescue Effect of Human Fetal RPE Cells in Retinal Degeneration Mouse Model.Investigative ophthalmology & visual science · 2020Article
- LncEGFL7OS regulates human angiogenesis by interacting with MAX at the EGFL7/miR-126 locus.eLife · 2019Article
- Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization.Drug delivery · 2018Article
- Theme trends and knowledge structure on choroidal neovascularization: a quantitative and co-word analysis.BMC ophthalmology · 2018Article
- Polymorphisms in Selected Genes and Their Association with Age-Related Macular Degeneration in a Chinese Population.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- MiR-126 enhances VEGF expression in induced pluripotent stem cell-derived retinal neural stem cells by targeting spred-1.International journal of clinical and experimental pathology · 2018Article
- let-7 Contributes to Diabetic Retinopathy but Represses Pathological Ocular Angiogenesis.Molecular and cellular biology · 2017Article
- Strand and Cell Type-specific Function of microRNA-126 in Angiogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- miR-146a is upregulated during retinal pigment epithelium (RPE)/choroid aging in mice and repressesJournal of clinical & experimental ophthalmology · 2016Article
- Hedgehog Signaling Components Are Expressed in Choroidal Neovascularization in Laser-induced Retinal Lesion.Acta histochemica et cytochemica · 2016Article
- Current therapeutic developments in atrophic age-related macular degeneration.The British journal of ophthalmology · 2016Review
- Article
- RPE necroptosis in response to oxidative stress and in AMD.Ageing research reviews · 2015Review
- Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.Drugs & aging · 2015Review
- Antiangiogenic and Neurogenic Activities of Sleeping Beauty-Mediated PEDF-Transfected RPE Cells In Vitro and In Vivo.BioMed research international · 2015Article
- Repression of choroidal neovascularization through actin cytoskeleton pathways by microRNA-24.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is the leading cause of severe visual loss and blindness over the age of 50 in developed countries. Vascular endothelial growth factor (VEGF) is considered as a critical molecule in the pathogenesis of choroidal neovascularization (CNV), which characterizes the neovascular AMD. Anti-VEGF agents are considered the most promising way of effectively inhibition of the neovascular AMD process. VEGF is a heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Two anti-VEGF agents have been approved by the US Food and Drug Administration (FDA) for the treatment of neovascular AMD. Pegaptanib sodium, which is an aptamer and ranibizumab, which is a monoclonal antibody fragment. Another humanized monoclonal antibody is currently off-label used, bevacizumab. This paper aims to discuss in details the effectiveness, the efficacy and safety of these three anti-VEGF agents. New anti-VEGF compounds which are recently investigated for their clinical usage (VEGF-trap, small interfering RNA) are also discussed for their promising outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.